There are no conversations in this channel.
Please log in to your account to view your subscribed posts.
| Topics | Statistics | Last Post | ||
|---|---|---|---|---|
|
1 response
3,022 views
0 reactions
|
by Lab7 Systems
09-09-2013, 06:57 AM
|
|||
|
1 response
2,618 views
0 reactions
|
09-05-2013, 06:24 AM
|
|||
|
0 responses
1,946 views
0 reactions
|
by lexogen
08-24-2013, 07:54 AM
|
|||
|
0 responses
4,070 views
0 reactions
|
by Genohub
08-15-2013, 08:49 AM
|
|||
|
0 responses
3,852 views
0 reactions
|
by SNPsaurus
08-04-2013, 10:22 PM
|
|||
|
1 response
2,471 views
0 reactions
|
by lexogen
07-31-2013, 06:40 AM
|
|||
|
0 responses
1,471 views
0 reactions
|
by epibio
07-22-2013, 06:37 AM
|
|||
|
5 responses
5,795 views
0 reactions
|
by austinso
06-28-2013, 09:57 PM
|
|||
|
1 response
2,408 views
0 reactions
|
by NuGEN
05-23-2013, 12:15 PM
|
|||
|
1 response
2,273 views
0 reactions
|
by ortex
05-07-2013, 11:55 PM
|
No topics found.
widgetinstance 229 (Webinars) skipped due to lack of content & hide_module_if_empty option.
-
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...Today, 11:48 AM -
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM -
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...07-08-2026, 05:17 AM